Resolvin D2 (RvD2) is produced physiologically from the sequential oxygenation of docosahexaenoic acid (DHA) by 15- and 5-lipoxygenases. RvD2 reduces polymorphonuclear leukocyte transendothelial migration, the earliest event in acute inflammation, by ~70% at doses as low as 10 pg in the mouse model of peritonitis. In the rat model of burn injury and sepsis, RvD2 restores defective neutrophil motility and dramatically increases survival at doses of 8-10 ng/rat. Resolvins also enhance bacterial clearance by phagocytosis and have been shown to synergistically enhance certain antibiotics. Cayman’s Resolvin D2 ELISA Kit is a competitive assay that can be used for quantification of RvD2. Due to the number and variation of potential sample types, this assay has been validated in Cayman’s ELISA Buffer (Item No. 400060) diluted to 1X (0.1 M potassium phosphate containing 0.1% BSA, 400 mM sodium chloride, 1 mM EDTA, and 0.01% sodium azide), human plasma, and human serum. The assay has a range from 1.6-1,000 pg/ml and a sensitivity (80% B/B0) of approximately 10 pg/ml.